Provider review
Sesame Care Review: Its Weight-Loss Claim Is Lower Than Its Own Trial
Sesame Care advertises the Wegovy pill with a single efficacy number: "Lose up to 14% of your weight." The registered trial behind that product, OASIS 4, reported a mean of 14.4% — so for once the number on the marketing page is lower than the number in the registry, not higher. Two things follow. The quantifier is still wrong, because "up to" describes a ceiling and 14.4% was an average, which means about half the participants in that trial lost more. And the product is FDA-approved, so unlike nearly everything else reviewed on this site, the study actually tested the thing being sold.
FDA-approved only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens sesamecare.com. A link is not a recommendation to take anything.
Provenance
What Sesame Care actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Wegovy® pill (oral semaglutide) — "Starting at just $149/month" for the pill, quoted separately from "access to GLP-1s & more, as low as $59/mo" for the care. Sesame charges for the care and the manufacturer's pharmacy channel charges for the drug, so a reader's real total is the sum. ⚠ Doseworth prices this company properly, including the fact that its program fee bills every 28 days rather than monthly.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to Sesame Care.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Sesame Care’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Wegovy® pill (oral semaglutide)Semaglutide · FDA-approvedClaim matches the trials
“GLP-1 weight loss, now in pill form. Lose up to 14% of your weight with the Wegovy® pill, starting at just $149/month. No needles required. […] Weight loss medication — Online weight loss care, access to GLP-1s & more, as low as $59/mo.”
Phase 3 trials
- NCT05564117 OASIS 4 — Phase 3, completed, n=307. Oral semaglutide 25 mg in adults with overweight or obesity. Registry-verified 2026-08-11: primary outcome "Percentage Change in Body Weight", reported as −14.4% on oral semaglutide against −2.5% on placebo. The drug-attributable difference is about 11.9 percentage points.
- NCT05035095 OASIS 1 — Phase 3, completed, n=667. The larger sibling trial, testing oral semaglutide at 50 mg rather than 25 mg, with the same primary outcome. Included because it is the other registered oral-semaglutide obesity trial and a reader checking the claim will find it — it is not the dose behind the Wegovy pill.
The number is right, the product is right, and the direction of the error is one this site almost never sees. OASIS 4 reported a mean 14.4% reduction in body weight on oral semaglutide 25 mg; Sesame advertises "up to 14%". A company inclined to overstate had room to claim more and did not. ⚠ Two qualifications belong on it. First, "up to" is the wrong quantifier for a mean: 14.4% was the average result, so roughly half the trial's participants lost more than 14% and the phrasing implies a ceiling where the trial reported a midpoint. Second, the placebo arm lost 2.5%, so the effect attributable to the drug is about 11.9 percentage points rather than the full 14 — a distinction no seller in this category makes, and one worth holding on to when comparing any two of these numbers.1
Dispensing chain
Who actually fills your prescription
Read the full account
Sesame is a marketplace rather than a compounder, and states the arrangement plainly: "Sesame-affiliated provider practices are independently owned and operated by licensed clinicians who provide clinical services using the Sesame telehealth platform." Its headline GLP-1 offer is an FDA-approved finished drug dispensed through the manufacturer's own pharmacy channel, so the question this field usually asks — which compounding pharmacy made this — does not arise for that product in the way it does elsewhere on this site. No compounding pharmacy is named because no compounded preparation is the subject of the claim reviewed here.
Read on August 2026 from https://sesamecare.com/
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number or potency result is published, and for the product reviewed here that is the expected answer rather than a gap: an FDA-approved finished drug carries its manufacturer's own quality system and an NDC, so batch documents are not something a telehealth marketplace would hold or publish. This field would matter if Sesame sold a compounded preparation under its own name; the claim reviewed here is for an approved product.
Read on August 2026 from https://sesamecare.com/
Licensing
Licensed to dispense, and where
Coverage
Sesame publishes no state list, included set or excluded set for its weight-loss service on the surfaces reachable without an account, so nothing here could be tested first-party and no coverage is claimed below.
Read the full licensing claim
"Sesame-affiliated provider practices are independently owned and operated by licensed clinicians who provide clinical services using the Sesame telehealth platform." Sesame states it is the platform and not the practice, which is a clearer separation than most of this roster draws.
Read on August 2026 from https://sesamecare.com/
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its headline efficacy number is lower than the trial it comes from — "up to 14%" against a registered mean of 14.4% — which is the opposite of the error this site usually documents.
- The product behind the claim is FDA-approved, so the trial tested the thing being sold rather than a branded analog of it.
- It names the product outright — the Wegovy® pill — rather than selling "a GLP-1" of unstated molecule, which several companies reviewed here do.
Show 3 more
- It states plainly that it is a platform and that the clinical practices are independently owned, rather than implying it employs the clinicians.
- The care price and the medication price are quoted as separate figures rather than merged into one number that hides which is which.
- No FDA warning letter, screened against the live index with a working positive control.
- "Up to 14%" attaches a ceiling quantifier to what was a mean result, so the phrasing misdescribes the shape of the evidence even though the magnitude is conservative.
- The placebo arm in OASIS 4 lost 2.5%, and no marketing number anywhere in this category is net of that — the drug-attributable difference is about 11.9 points, not 14.
- No trial is named on the page, so a reader cannot check the 14% against anything without knowing which study to look for.
Show 2 more
- The advertised "$149/month" for the pill and "as low as $59/mo" for the care are quoted separately and never added together, so no single figure on the page is what a patient actually pays.
- No state list is published on the surfaces reachable without an account.
Verdict
The bottom line
Sesame Care is the rare company on this site whose efficacy claim needs defending rather than deflating. It advertises "up to 14%" weight loss with the Wegovy pill; OASIS 4 reported 14.4%, so the number on the page sits just under the number in the registry. The product is FDA-approved, which means the study tested what is actually dispensed — a sentence that cannot be written about most of this roster. What remains is a framing problem rather than an evidence problem: "up to" implies a maximum where the trial reported an average, and no figure here is net of the 2.5% the placebo arm lost. Sesame also sells care and medication as two separate prices, so the honest answer to what it costs is a sum it never prints. As a route to an approved oral GLP-1 it is straightforward; as a source of a single number to plan around, it is not.
Opens sesamecare.com. A link is not a recommendation to take anything.
A claim below its own evidence
Sesame's home page carries one efficacy number:
"GLP-1 weight loss, now in pill form. Lose up to 14% of your weight with the Wegovy® pill, starting at just $149/month. No needles required."
The trial behind the Wegovy pill is OASIS 4 (NCT05564117) — oral semaglutide 25 mg in adults with overweight or obesity. Verified in the registry on 11 August 2026:
- Status — Completed
- Phase — 3
- Participants — 307
- Primary outcome — Percentage change in body weight
- Result — −14.4% on oral semaglutide, against −2.5% on placebo
So the advertised figure is below the registered result. On a site that spends most of its time documenting claims that reach past their evidence, this is worth stating plainly: Sesame had room to claim more and did not.
Full analysis — 3 more sectionsWhere the framing still goes wrong · The part that makes this review different · What it is, and what that means for price
Where the framing still goes wrong
"Up to 14%" describes a ceiling. 14.4% was a mean. Those are different statements about the same trial, and the difference matters in both directions: about half the participants lost more than 14.4%, and a substantial number lost considerably less. A reader told "up to 14%" will reasonably plan for less than 14% and may be surprised in either direction.
The second qualification applies to every number in this category and is almost never made. The placebo arm in OASIS 4 lost 2.5% of body weight. The effect attributable to the drug is therefore about 11.9 percentage points, not 14.4. Every trial in this class enrolls people into a program of diet and activity support alongside the drug, and that program does some of the work.
The part that makes this review different
Nearly every claim assessed on this site carries the same caveat: the trial tested an FDA-approved product, and the company dispenses a compounded preparation that has never been through a registered trial.
That caveat does not apply here. The Wegovy pill is an approved finished drug with an NDC, dispensed through the manufacturer's own channel. Whatever else is true of Sesame's marketing, the study behind its number tested the thing it is selling.
What it is, and what that means for price
Sesame states its own structure clearly:
"Sesame-affiliated provider practices are independently owned and operated by licensed clinicians who provide clinical services using the Sesame telehealth platform."
It is a marketplace. It charges for access to care — "as low as $59/mo" — and the medication is billed separately at "$149/month". Neither number is the cost of treatment; the sum is, and the page never prints it.
Questions
Frequently asked questions
Is "lose up to 14%" accurate?
It is conservative, which is unusual here. OASIS 4 (NCT05564117), the phase 3 trial of oral semaglutide 25 mg in 307 adults with overweight or obesity, reported a mean weight change of −14.4% against −2.5% on placebo. Sesame advertises "up to 14%", a number below its own evidence. The framing is still imprecise: "up to" implies a ceiling where the trial reported an average, so roughly half the participants lost more. And no advertised figure in this category is net of the placebo arm — the drug-attributable difference here is about 11.9 percentage points.
Is the Wegovy pill the same as compounded semaglutide?
No, and the difference runs the right way for once. The Wegovy pill is an FDA-approved finished drug with a manufacturer's quality system behind it, so OASIS 4 tested the product Sesame is selling. Almost every other claim reviewed on this site has to carry the opposite caveat — that the trial tested the approved drug while the seller dispenses a compounded preparation that has never been through a registered trial of any kind.
What does Sesame actually cost?
Two numbers that are never added together: "as low as $59/mo" for the weight-loss care and "starting at just $149/month" for the pill. A patient pays both. Our sister site prices this company in detail, including the fact that Sesame's program fee bills every 28 days rather than monthly — which makes a year thirteen charges rather than twelve.
Has Sesame Care had an FDA warning letter?
No. FDA's live warning-letter index was queried on August 11, 2026 for "sesame care". It returned five rows, and their company columns read Revolution Foods PBC, Sanitation & Environmental Technology Institute dba SDWH, Ayuryoga Inc. and two others — the phrase matched inside letters addressed to other businesses. A query for "strut" in the same pass returned Strut Health's real letter, which is what makes this zero evidence rather than a sign of a broken search.
Glossary
Key terms
Show definitions
- "Up to"
- A ceiling. When a trial reports a mean, roughly half the participants fall above it and half below, so "up to the mean" describes neither the typical result nor the maximum. It is the most common quantifier in this category and almost always the wrong one.
- Placebo-adjusted effect
- The difference between what the treatment arm lost and what the placebo arm lost. In OASIS 4 that is 14.4% minus 2.5%, or about 11.9 percentage points. Marketing figures in this category are gross rather than placebo-adjusted, which flatters every drug in it equally.
- FDA-approved finished drug
- A product that has been through the approval process and carries an NDC, manufactured under the sponsor's own quality system. Distinct from a compounded preparation, which is made for an individual patient by a pharmacy and has not been evaluated by FDA for safety, effectiveness or quality.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Sesame Care's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 1 sources
- Knop FK, Aroda VR, do Vale RD, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 402(10403):705-719. https://pubmed.ncbi.nlm.nih.gov/37385278/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.